Search results for "Patient survival"

showing 6 items of 16 documents

Low molecular weight heparins as antineoplastic agents.

2008

There is an increasing interest in the potential role of low molecular weight heparins (LMWHs) in the management of cancer patients. These antithrombotic agents have generated particular excitement because they have been proved useful in both the prevention and treatment of venous thromboembolism (VTE) in patients with malignancy. Recent reports are, at the same time, highlighting a potential role of LMWHs on patient survival due to their presumed antineoplastic action. This review will discuss the most recent reports and patents on these topics.

OncologyCancer Researchmedicine.medical_specialtyClinical Trials as Topicbusiness.industryCancerPatient survivalAntineoplastic AgentsGeneral MedicineHeparin Low-Molecular-WeightMalignancymedicine.diseaseSurvival RateLow molecular weight heparin cancer therapyOncologyInternal medicineNeoplasmsDrug DiscoveryAntithromboticmedicineHumansPharmacology (medical)In patientbusinessVenous thromboembolismRecent patents on anti-cancer drug discovery
researchProduct

Administration of low molecular weight heparins for prolonging the survival of patients with cancer

2015

Thromboembolism represents one of the most common causes of mortality and morbidity in cancer patients, and thromboembolic events occur more often in patients with biologically more aggressive malignant disease. Therefore, low molecular weight heparins (LMWHs) are routinely administered to cancer patients. Importantly, in addition to the prophylactic activity against thromboembolism, LMWHs seem to decrease mortality in these patients. Improved clinical prognosis is independent of the antithrombotic efficacy, since vitamin K antagonists do not improve patient survival, and non-anticoagulant heparins exhibit a similar anti-cancer effect. This protective effect is primarily related to the prev…

Oncologymedicine.medical_specialtybusiness.industryCancerPatient survivalHeparinheparinmedicine.diseaseMetastasispatient survivalInternal medicinecancermetastasisMedicinebusinessAdministration (government)medicine.drugPhlebological Review
researchProduct

Mapping and quantification of biomolecules in tumor biopsies using bioluminescence

1996

Quantitative bioluminescence and single-photon imaging have been applied for mapping concentration distributions of metabolites, such as adenosine triphosphate (ATP), glucose and lactate, in biopsies of cervical cancers in patients. Biopsies were taken before a conventional radiation treatment, and a number of clinically relevant data, such as local tumor control, patient survival, metastatic spread and so forth, were documented. There was no correlation between staging or grading and any of the metabolic parameters measured. Local correlations between ATP, glucose and lactate on a pixel-to-pixel basis were generally positive, with respective Spearman's correlation coefficients less in pati…

Pathologymedicine.medical_specialtyBiopsyUterine Cervical NeoplasmsBiologyStatistics NonparametricMetastasisNecrosisCellular and Molecular NeuroscienceAdenosine TriphosphateNeoplasmsmedicineHumansBioluminescenceIn patientNeoplasm MetastasisMolecular BiologyGrading (tumors)Neoplasm StagingPharmacologyMetabolic imagingSingle photon imagingPatient survivalCell Biologymedicine.diseaseTumor controlSurvival RateGlucoseLuminescent MeasurementsLactatesMolecular MedicineFemaleEnergy MetabolismExperientia
researchProduct

Predicting survival after transarterial chemoembolization for hepatocellular carcinoma using a neural network: A Pilot Study.

2019

BACKGROUND AND AIMS Deciding when to repeat and when to stop transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) can be difficult even for experienced investigators. Our aim was to develop a survival prediction model for such patients undergoing TACE using novel machine learning algorithms and to compare it to conventional prediction scores, ART, ABCR and SNACOR. METHODS For this retrospective analysis, 282 patients who underwent TACE for HCC at our tertiary referral centre between January 2005 and December 2017 were included in the final analysis. We built an artificial neural network (ANN) including all parameters used by the aforementioned risk scores a…

medicine.medical_specialtyCarcinoma Hepatocellular610 MedizinPilot Projects03 medical and health sciences0302 clinical medicine610 Medical sciencesmedicineHumansIn patientInternal validationChemoembolization TherapeuticRetrospective StudiesHepatologyArtificial neural networkbusiness.industryLiver NeoplasmsPatient survivalClinical routinemedicine.diseaseTreatment Outcome030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyRadiologyNeural Networks ComputerbusinessArea under the roc curvePredictive modellingLiver international : official journal of the International Association for the Study of the LiverREFERENCES
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Longterm Survival After Liver Transplantation for Autoimmune Hepatitis : Results From the European Liver Transplant Registry

2020

The aim of this study was to analyze longterm patient and graft survival after liver transplantation for autoimmune hepatitis (AIH-LT) from the prospective multicenter European Liver Transplant Registry. Patient and liver graft survival between 1998 and 2017 were analyzed. Patients after AIH-LT (n = 2515) were compared with patients receiving LT for primary biliary cholangitis (PBC-LT; n = 3733), primary sclerosing cholangitis (PSC-LT; n = 5155), and alcohol-related cirrhosis (AC-LT; n = 19,567). After AIH-LT, patient survival was 79.4%, 70.8%, and 60.3% and graft survival was 73.2%, 63.4%, and 50.9% after 5, 10, and 15 years of follow-up. Overall patient survival was similar to patients af…

medicine.medical_specialtyCirrhosismedicine.medical_treatmentCholangitis SclerosingMedizinAutoimmune hepatitis030230 surgeryLiver transplantationGastroenterologyPrimary sclerosing cholangitis03 medical and health sciences0302 clinical medicineInternal medicinemedicineLiving DonorsHumansProspective StudiesRegistriesTransplantationHepatologybusiness.industryLiver Cirrhosis BiliaryHazard ratioPatient survivalmedicine.diseasedigestive system diseasesLiver TransplantationHepatitis AutoimmuneIncreased risk030211 gastroenterology & hepatologySurgeryGraft survivalbusiness
researchProduct